Latest Tris Stories

MONMOUTH JUNCTION, N.J., March 11, 2013 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, announced today receipt of a first milestone payment under its U.S. prescription cough/cold collaboration with Vernalis plc (Vernalis). This milestone recognizes the achievement by Tris of proof-of-concept (POC) for the first collaboration compound, CCP-01. Under the collaboration, POC required the successful...

MONMOUTH JUNCTION, N.J., Nov. 15, 2012 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, announced the appointment of Jonathan Berlent as Vice President of Business Development. He will lead Tris' product and technology partnering, and collaborate with branded pharmaceutical companies on their life cycle management opportunities. "As Tris scales up its effort to address the growing unmet need in the...

MONMOUTH JUNCTION, N.J., July 11, 2012 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company with fully integrated commercial manufacturing and drug development operations, announced today that in order to meet demand for its products (approved and near term) the company has fortified its supply chain, increased manufacturing capacity and strengthened its management team. During the past two months, Tris has been fortunate to receive five new ANDA approvals from the...

MONMOUTH JUNCTION, N.J., May 31, 2012 /PRNewswire/ -- Tris Pharma, a technology driven specialty pharmaceutical company, announced today that the US Food and Drug Administration (FDA) has approved the first-ever generic to Delsym®, an extended-release oral liquid suspension containing dextromethorphan polistirex. Delsym was approved in 1982 and there has never been any generic alternative approved until now. Tris has pioneered the delivery of drugs in taste-neutral, extended...

MONMOUTH JUNCTION, N.J., May 10, 2012 /PRNewswire/ -- Tris Pharma, a technology driven specialty pharmaceutical company, announced today the joining of Ms. Amanda Wohlleber as Vice President of Scale up and Technical Services effective immediately and the promotion of their key manufacturing executive, Rajul Parikh. Amanda brings more than 20 years of pharmaceutical manufacturing and tech service experience to Tris' technology and manufacturing teams. "With our continued growth and...

Chlorinated Tris Linked to Cancer, Removed from Children's Pajamas in 1970's BERKELEY, Calif., Oct. 12, 2011 /PRNewswire-USNewswire/ -- The same chemical removed from baby pajamas in 1977 due to concerns about carcinogenicity, was officially listed as a cancer-causing chemical by the State of California on the "Prop 65 list" today. Chlorinated Tris is the most commonly used flame retardant in foam in U.S. furniture and baby products. The listing won't ban the chemical from use but could...

MONMOUTH JUNCTION, N.J., Aug. 18, 2011 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, has appointed Mr. Dominick DiPaolo to the position of Vice President of Quality, and Mr. Adam Drapczuk III as Controller and Director of Finance. They bring extensive backgrounds in their respective areas of expertise to the company as the newest members of Tris leadership team. "Tris' emphasis on innovation has paid dividends via a...

MONMOUTH JUNCTION, N.J., June 29, 2011 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, has appointed Ms. Cheryl Patnick to the position of Vice President of Human Resources. Ms. Patnick had been working with Tris as a consultant for about a year, and will now lead and manage Tris' human resource activities as an executive of the company. "Tris is at a point in its evolution where it needs leaders who are willing to take...

MONMOUTH JUNCTION, N.J., March 29, 2011 /PRNewswire/ -- Tris Pharma, Inc., a specialty pharmaceutical company, announced today the highly anticipated re-launch of the MyKidz® Iron product line. Since the 2007 launch of MyKidz Iron, it has attracted a loyal following of pediatricians, pediatric nurses and mothers. When the previous marketer decided to focus its product pipeline in a different direction, availability of MyKidz Iron(TM) became limited, but the need for a great tasting...

MONMOUTH JUNCTION, N.J., Oct. 7 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced the US Food and Drug Administration (FDA) has approved first-ever generic of TUSSIONEX®, an Extended-Release Suspension containing hydrocodone polistirex and chlorpheniramine polistirex. Tussionex was approved in the 1980's based on 1970's technology involving organic solvent based coatings. Based on its highly versatile,...